Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

Inclusion Criteria8

• years of age or older
• Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
• One of the following:
• Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment
• Completed chemotherapy with no cardiotoxicity at least two years post treatment
• Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity
• An understanding of the protocol and its requirements, risks, and discomforts
• The ability and willingness to sign an informed consent